The role of Janus kinase inhibitors in the treatment of juvenile idiopathic arthritis

Juvenile idiopathic arthritis (JIA) presents ongoing treatment challenges despite advances in treatment over the last few years. This review presents that recent studies highlight the potential of Janus kinase inhibitors (JAKi) to significantly reduce disease activity. However, concerns about long-term safety, including cardiovascular risks and malignancy, underscore the need for more research. While JAKi offers a promising therapeutic avenue in pediatric rheumatology, the long-term safety profile requires further investigation to assert its place in standard treatment guidelines.